Miyakoshi, Jun
Yazaki, Shu
Shimoi, Tatsunori
Onishi, Mai
Saito, Ayumi
Kita, Shosuke
Yamamoto, Kasumi
Kojima, Yuki
Sumiyoshi-Okuma, Hitomi
Nishikawa, Tadaaki
Sudo, Kazuki
Noguchi, Emi
Murata, Takeshi
Shiino, Sho
Takayama, Shin
Suto, Akihiko
Fujiwara, Yasuhiro
Yoshida, Masayuki http://orcid.org/0000-0002-7198-8357
Yonemori, Kan
Article History
Received: 19 May 2023
Revised: 18 August 2023
Accepted: 23 August 2023
First Online: 5 September 2023
Declarations
:
: This study was approved by the Institutional Review Board of the National Cancer Center (No. 2014–092).
: Masayuki Yoshida reports personal fees from Roche Japan, Eli Lilly, Chugai, MSD, Daiichi Sankyo, Ono, Agilent technologies outside of the submitted work. Tadaaki Nishikawa reports personal fees from Takeda Pharmaceutical Company, Eisai, and AstraZeneca outside of the submitted work. Emi Noguchi reports personal fees from Pfizer, Taiho, Eli Lilly, AstraZeneca, Chugai, and Eisai outside the submitted work. Kan Yonemori reports receiving grants from Merck Sharp & Dohme, Daiichi-Sankyo, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Seattle Genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe; personal fees from Pfizer, Eisai, Astrazeneca, Eli Lilly, Takeda, Chugai, MSD, FujiFilm Pharma, Bayer, Asteras, Boeringer Ingelheim, Daiichi Sankyo, PDR pharma, Sanofi outside the submitted work.
: The need for informed consent was waived because of the retrospective nature of the study.